重大事件
即時報告
8-K
2026-06-23
Agenus股東年會通過六項提案 包括增發股權激勵及期權交換計劃
AI 繁中摘要
Agenus Inc. 提交 8-K 表格，報告 2026 年 6 月 16 日舉行的股東年會投票結果。📊 出席或代表投票的股份共 27,098,077 股，佔已發行及合資格投票股份的 65.24%，達到法定人數。
六項提案全部獲得通過：
1. 選舉 Garo Armen 及 Jennifer Buell 為第二類董事，任期三年，至 2029 年股東年會結束。投票結果：Armen 獲得 13,371,144 票贊成、6,116,636 票 withheld；Buell 獲得 13,914,203 票贊成、5,573,577 票 withheld。兩者均有 7,610,297 票為經紀人非投票。
2. 批准修訂 2019 年員工購股計劃，將授權發行股份由 15 萬股增至 20 萬股。贊成 15,162,365 票，反對 4,154,008 票，棄權 171,407 票，經紀人非投票 7,610,297 票。
3. 批准修訂 2019 年股權激勵計劃，增加 500 萬股授權發行股份。贊成 12,985,390 票，反對 6,331,359 票，棄權 171,031 票，經紀人非投票 7,610,297 票。
4. 批准一次性股票期權交換計劃，涵蓋 2019 年、2009 年及 2015 年激勵計劃，董事及高級管理人員的更換期權設有溢價行使價。贊成 10,034,030 票，反對 9,252,690 票，棄權 201,060 票，經紀人非投票 7,610,297 票（此項反對票比例較高，但仍有足夠贊成票通過）。
5. 通過非約束性諮詢投票，批准 2025 年度指定高管的薪酬。贊成 12,751,266 票，反對 6,507,225 票，棄權 229,289 票，經紀人非投票 7,610,297 票。
6. 批准委任 KPMG LLP 為截至 2026 年 12 月 31 日止財政年度的獨立註冊會計師事務所。贊成 24,100,465 票，反對 2,501,607 票，棄權 496,005 票，無經紀人非投票。
對投資者的潛在影響：所有提案均獲通過，反映股東對管理層及董事會的持續支持，尤其是股權激勵計劃及購股計劃的擴充，有助吸引及挽留人才。不過，期權交換計劃的反對票接近贊成票，顯示部分股東對攤薄效應或有保留。整體而言，公司治理流程順利，短期內不會對股價構成重大負面影響。💰
展開英文正文
8-K false000109897200010989722026-06-162026-06-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2026 AGENUS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 000-29089 06-1562417 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 3 Forbes Road Lexington, Massachusetts 02421 (Address of Principal Executive Offices) (Zip Code) Registrant’s Telephone Number, Including Area Code: 781 674-4400 (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 par value per share AGEN The Nasdaq Stock Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 5.07 Submission of Matters to a Vote of Security Holders. Agenus Inc. (the “Company”) held its Annual Meeting of Stockholders on June 16, 2026 (the “Annual Meeting”). A total of 27,098,077 shares of common stock, representing 65.24% of the shares outstanding and eligible to vote and constituting a quorum, were present at the Annual Meeting or represented by valid proxies. At the Annual Meeting, the Company’s stockholders voted on the following matters, which are described in detail in the Company’s Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 22nd, 2026: (i) to elect Garo Armen and Jennifer Buell as Class II Directors, each for a term of three years expiring at the 2029 Annual Meeting of Stockholders (“Proposal 1”); (ii) to approve an amendment to the Company’s 2019 Employee Stock Purchase Plan (as amended) to increase the number of shares of common stock authorized for issuance thereunder from 150,000 shares to 200,000 shares (“Proposal 2”); (iii) to approve an amendment to the Company’s Amended and Restated 2019 Equity Incentive Plan (“2019 EIP”) to increase the aggregate shares available for issuance by 5,000,000 shares (“Proposal 3”); (iv) to approve a one-time stock option exchange program under the Company’s 2019 EIP, the Amended and Restated 2009 Equity Incentive Plan, and the Company’s 2015 Inducement Equity Plan, with premium strike prices applicable to director and executive officer replacement options (“Proposal 4”); (v) to approve, in a non-binding advisory vote, the compensation of the Company’s named executive officers for 2025 (“Proposal 5”) and (vi) to ratify the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 (“Proposal 6”). The Company’s stockholders approved the Class II Director nominees recommended for election in Proposal 1 at the Annual Meeting. The votes cast at the Annual Meeting were as follows: Class II Director Nominee For Withheld Broker Non-Votes Garo Armen 13,371,144 6,116,636 7,610,297 Jennifer Buell 13,914,203 5,573,577 7,610,297 The Company’s stockholders approved Proposal 2. The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 15,162,365 4,154,008 171,407 7,610,297 The Company’s stockholders approved Proposal 3. The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 12,985,390 6,331,359 171,031 7,610,297 The Company’s stockholders approved Proposal 4. The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 10,034,030 9,252,690 201,060 7,610,297 The Company’s stockholders approved Proposal 5. The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 12,751,266 6,507,225 229,289 7,610,297 The Company’s stockholders approved Proposal 6. The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 24,100,465 2,501,607 496,005 0 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 23, 2026 By: /s/ Garo H. Armen Garo H. Armen Chairman and CEO